Neurocrine Biosciences, Inc. (NBIX)
NASDAQ: NBIX · Real-Time Price · USD
131.24
-3.89 (-2.88%)
At close: Jul 15, 2025, 4:00 PM
133.98
+2.74 (2.09%)
After-hours: Jul 15, 2025, 7:44 PM EDT
Neurocrine Biosciences Stock Forecast
Stock Price Forecast
The 21 analysts that cover Neurocrine Biosciences stock have a consensus rating of "Strong Buy" and an average price target of $165.14, which forecasts a 25.83% increase in the stock price over the next year. The lowest target is $115 and the highest is $219.
Price Target: $165.14 (+25.83%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Neurocrine Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 7 | 7 | 7 | 8 |
| Buy | 11 | 11 | 11 | 11 | 11 | 11 |
| Hold | 4 | 4 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 21 | 21 | 20 | 20 | 20 | 21 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Goldman Sachs | Goldman Sachs | Strong Buy Initiates $182 | Strong Buy | Initiates | $182 | +38.68% | Jul 10, 2025 |
| UBS | UBS | Strong Buy Maintains $152 → $174 | Strong Buy | Maintains | $152 → $174 | +32.58% | Jul 9, 2025 |
| RBC Capital | RBC Capital | Buy Reiterates $145 | Buy | Reiterates | $145 | +10.48% | Jun 2, 2025 |
| Piper Sandler | Piper Sandler | Buy Reiterates $160 → $154 | Buy | Reiterates | $160 → $154 | +17.34% | May 6, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $137 → $145 | Buy | Maintains | $137 → $145 | +10.48% | May 6, 2025 |
Financial Forecast
Revenue This Year
2.74B
from 2.36B
Increased by 16.25%
Revenue Next Year
3.16B
from 2.74B
Increased by 15.23%
EPS This Year
3.99
from 3.29
Increased by 21.15%
EPS Next Year
6.18
from 3.99
Increased by 55.14%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3.0B | 3.5B | 4.0B | ||
| Avg | 2.7B | 3.2B | 3.5B | ||
| Low | 2.5B | 2.8B | 3.0B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 25.3% | 27.8% | 26.5% | ||
| Avg | 16.2% | 15.2% | 12.3% | ||
| Low | 8.2% | 0.8% | -3.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 4.92 | 7.94 | 12.01 | ||
| Avg | 3.99 | 6.18 | 8.31 | ||
| Low | 2.88 | 4.03 | 3.53 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 49.7% | 99.1% | 94.2% | ||
| Avg | 21.2% | 55.1% | 34.4% | ||
| Low | -12.4% | 1.0% | -42.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.